At the IASLC WCLC 2021 virtual meeting, Boehringer Ingelheim presented the latest updates on the afatinib* real world data in advanced non-small cell lung cancer (NSCLC).
Please see below for more information and a downloadable version of the publication.
Product theater showcase
Thinking Beyond KRAS G12C Inhibition in NSCLC
Watch as our experts – Victoria Zazulina, Darryl McConnell, and Kristie Fernamberg – engage in a roundtable discussion about KRAS-mutant NSCLC and recent advances in the treatment of this disease. The discussion includes conversation on Boehringer Ingelheim’s approach for targeting mutations beyond KRAS G12C.
Pushing Checkpoint Inhibition Beyond PD-1
Our experts – Victoria Zazulina, Michael Merger, and Sophia Valai –present emerging immuno-oncology strategies for treating NSCLC, highlighting combinations of PD-1 checkpoint inhibition with STING agonism, VEGF/Ang2 inhibition, SIRPα and MDM2-p53 antagonism, as well as the potential role of oncolytic viruses and T-cell engagers in immune-oncology therapy.
Browse through the publications below to learn more about our latest clinical trials with afatinib.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: September 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue